chpt1 Antibody

What is CHPT1 and what is its biological significance?

CHPT1 (Choline Phosphotransferase 1) is an enzyme that plays a crucial role in the cytidine diphosphate-choline (Kennedy) pathway, specifically catalyzing the final step in phosphatidylcholine (PC) synthesis. CHPT1 is primarily localized in the Golgi apparatus, where it selectively synthesizes PC, unlike its counterpart CEPT1 (Choline/Ethanolamine Phosphotransferase 1) which can synthesize both PC and phosphatidylethanolamine (PE) in the endoplasmic reticulum . The protein has a calculated molecular weight of approximately 45 kDa and consists of 406 amino acids . The CHPT1 gene is located on chromosome 12 in humans with the gene ID 56994 . The enzyme's activity is critical for maintaining membrane phospholipid composition and cellular function, as PC is a major component of cellular membranes and has roles in cell signaling and lipid metabolism.

What are the primary applications of CHPT1 antibodies in research?

CHPT1 antibodies serve multiple research applications, with varying specificity and utility depending on the experimental context:

When selecting an antibody for a specific application, researchers should consider the validation data provided by manufacturers and previous literature reports demonstrating successful use in the intended application .

What are the key considerations for validating a new CHPT1 antibody?

Validating a CHPT1 antibody is critical before employing it in extensive research protocols. A comprehensive validation approach should include:

• Specificity assessment: Verify single band detection at the expected molecular weight (~45 kDa) using Western blot analysis . Consider using lysates from cells with known CHPT1 expression, such as DU145 as demonstrated in published validation data .

• Knockout/knockdown controls: Ideally, include CRISPR-generated CHPT1-knockout cells as negative controls. The disappearance of signal in these samples confirms antibody specificity .

• Cross-reactivity testing: Check reactivity with related proteins, particularly CEPT1, to ensure the antibody specifically recognizes CHPT1 and not other phosphotransferases .

• Multiple detection methods: Validate using complementary techniques (e.g., immunofluorescence, mass spectrometry) to confirm consistent target recognition across different experimental conditions.

• Batch-to-batch consistency: When receiving new lots, perform comparison tests with previous lots to ensure consistent performance.

The validation process should be documented thoroughly and included in publications to support the reliability of research findings.

What are the optimal conditions for Western blot detection of CHPT1?

For optimal Western blot detection of CHPT1, consider the following methodological guidelines:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors

  • Load 25-30 μg of total protein per lane for cell lysates

  • Include phosphatase inhibitors if studying phosphorylation states

• Gel electrophoresis and transfer:

  • 10-12% SDS-PAGE gels are suitable for resolving the 45 kDa CHPT1 protein

  • Semi-dry or wet transfer to PVDF membranes (nitrocellulose is also acceptable)

• Blocking and antibody incubation:

  • Block with 3-5% non-fat dry milk in TBST (as used in validated protocols)

  • Primary antibody dilution: 1:500-1:2,000 (optimize for each specific antibody)

  • Incubate overnight at 4°C with gentle agitation

• Detection and visualization:

  • HRP-conjugated secondary antibodies at 1:10,000 dilution

  • ECL detection with 30-second exposure time (adjust based on signal strength)

• Controls:

  • Include positive control lysates (e.g., DU145 cells)

  • Consider using CHPT1 knockout cells as negative controls when available

This protocol has been validated using anti-CHPT1 antibodies in published research and provides a starting point for optimization based on specific experimental conditions .

How can I distinguish between CHPT1 and CEPT1 in experimental systems?

Distinguishing between CHPT1 and CEPT1 is crucial for understanding their differential roles in phospholipid synthesis. Consider these methodological approaches:

• Antibody-based differentiation:

  • Use antibodies targeting unique epitopes - CHPT1 antibodies targeting N-terminal regions (amino acids 7-33) provide specificity, as this region differs from CEPT1

  • Confirm specificity using knockout cell lines for each enzyme separately

• Subcellular localization:

  • CHPT1 predominantly localizes to the Golgi apparatus

  • CEPT1 primarily localizes to the endoplasmic reticulum

  • Use co-localization studies with organelle markers (e.g., GM130 for Golgi, calnexin for ER)

• Functional differentiation:

  • CHPT1 specifically synthesizes PC

  • CEPT1 synthesizes both PC and PE

  • Analyze phospholipid profiles in knockout models using lipidomics approaches

• Genetic approaches:

  • Use specific siRNA or CRISPR-based knockdown/knockout strategies

  • Validate knockdown efficiency using both protein detection and functional assays

• Enzymatic activity:

  • CEPT1 knockout reduces both PC (50%) and PE (80%) synthesis

  • CHPT1 knockout reduces only PC synthesis (50%)

These complementary approaches allow for reliable distinction between these related phosphotransferases and help elucidate their specific contributions to cellular phospholipid homeostasis.

What methodological considerations are important when using CHPT1 antibodies for immunofluorescence?

When using CHPT1 antibodies for immunofluorescence studies, consider these methodological factors:

• Cell fixation and permeabilization:

  • For Golgi-localized proteins like CHPT1, paraformaldehyde fixation (4%, 15 minutes) preserves structure

  • Mild permeabilization with 0.1-0.2% Triton X-100 or 0.1% saponin preserves Golgi morphology

  • Avoid methanol fixation which can disrupt membrane structures

• Antibody selection and validation:

  • Confirm the antibody is validated for immunofluorescence applications

  • Consider fluorophore-conjugated primary antibodies for direct detection

  • For unconjugated antibodies, select secondary antibodies with minimal cross-reactivity

• Co-localization studies:

  • Include Golgi markers (e.g., GM130, TGN46) to confirm CHPT1 localization

  • Consider co-staining with ER markers to distinguish from CEPT1 localization

  • Use high-resolution confocal or super-resolution microscopy for precise localization

• Controls and quantification:

  • Include CHPT1 knockout cells as negative controls

  • Perform quantitative co-localization analysis using appropriate software

  • Consider live-cell imaging with tagged CHPT1 to complement antibody-based detection

• Specialized applications:

  • For proximity studies with lipid droplets, consider proximity ligation assays

  • For studies of membrane domains, consider detergent resistance assays followed by immunofluorescence

These considerations help ensure reliable detection and localization of CHPT1 protein in cellular contexts while minimizing artifacts and misinterpretation.

How does CHPT1 contribute to lipid droplet biogenesis and what methodologies can reveal this relationship?

CHPT1's role in lipid droplet (LD) biogenesis involves its function in phosphatidylcholine synthesis, which is critical for LD formation and stability. Research methodologies to investigate this relationship include:

• Genetic manipulation approaches:

  • CRISPR/Cas9-mediated CHPT1 knockout significantly reduces lipid droplet size and number, indicating its essential role in LD biogenesis

  • Complementary experiments comparing CHPT1 and CEPT1 knockouts reveal differential contributions to LD formation

• Proximity analysis techniques:

  • Proximity ligation assays can detect CHPT1's physical proximity to cytoplasmic LDs

  • CHPT1 has been found in close proximity to LDs, suggesting direct involvement in providing phospholipids for the LD monolayer

• Lipid supplementation studies:

  • Exogenous PC supplementation in CHPT1-deficient cells can partially rescue LD formation defects

  • This approach distinguishes between direct and indirect effects of CHPT1 on LD biogenesis

• Comparative phospholipid analysis:

  • Lipidomic profiling of LD fractions from wild-type versus CHPT1-KO cells reveals specific PC species dependent on CHPT1 activity

  • PC composition analysis of LD surface monolayers helps identify CHPT1-derived phospholipids

• Localization studies during LD formation:

  • Time-course immunofluorescence tracking CHPT1 localization during oleate-induced LD formation

  • Super-resolution microscopy to visualize CHPT1 at ER-LD contact sites

This multifaceted approach has revealed that CHPT1 contributes to LD biogenesis through providing PC for the LD monolayer, with distinct roles compared to CEPT1-derived phospholipids .

What is the relationship between CHPT1 and CCTα regulation, and how can this be experimentally investigated?

The relationship between CHPT1 and CCTα (CTP:phosphocholine cytidylyltransferase, the rate-limiting enzyme in PC synthesis) represents a critical regulatory axis in phospholipid metabolism. Experimental approaches to investigate this relationship include:

• Genetic manipulation studies:

  • CEPT1 knockout, but not CHPT1 knockout, causes posttranscriptional induction of CCTα protein expression

  • CEPT1-KO cells show CCTα dephosphorylation and constitutive localization on the inner nuclear membrane and nucleoplasmic reticulum

  • These effects can be reversed by incubating CEPT1-KO cells with PC liposomes, suggesting end-product inhibition mechanisms

• Subcellular fractionation and localization:

  • Nuclei isolation followed by inner/outer nuclear membrane separation to track CCTα translocation

  • Immunofluorescence to visualize CCTα localization patterns in wild-type vs. CHPT1/CEPT1 knockout cells

• Phosphorylation analysis:

  • Western blotting with phospho-specific antibodies to monitor CCTα phosphorylation status

  • Phosphoproteomics to identify specific phosphorylation sites affected by CHPT1/CEPT1 deficiency

• Functional enzyme assays:

  • In vitro CCTα activity assays from cellular fractions to correlate localization with activity

  • Pulse-chase experiments with radiolabeled precursors to measure flux through the Kennedy pathway

• Lipidomic profiling:

  • Comprehensive analysis of phospholipid species in CHPT1 vs. CEPT1 knockout cells

  • Correlation of specific lipid changes with CCTα localization and activity

These methodologies have revealed that CEPT1-derived PC, rather than CHPT1-derived PC, provides feedback regulation of nuclear CCTα activity, suggesting compartmentalized roles for these phosphotransferases in maintaining cellular phospholipid homeostasis .

How can researchers distinguish between different PC species produced by CHPT1 versus CEPT1?

Distinguishing between phosphatidylcholine (PC) species produced by CHPT1 versus CEPT1 requires sophisticated lipidomic approaches combined with genetic manipulation:

• Targeted lipidomics methodology:

  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) with multiple reaction monitoring

  • High-resolution mass spectrometry to distinguish PC species based on fatty acid composition

  • Stable isotope labeling with precursors like deuterated choline to track newly synthesized PC

• Genetic manipulation approaches:

  • Generate single knockout cells for either CHPT1 or CEPT1 using CRISPR/Cas9

  • Create double knockout cells with rescue constructs expressing either CHPT1 or CEPT1

  • Employ inducible expression systems to control the timing of enzyme expression

• Subcellular fractionation:

  • Isolate Golgi and ER fractions to analyze compartment-specific PC profiles

  • Purify lipid droplets to examine PC species specifically incorporated into their monolayers

  • Analyze nuclear membrane fractions to identify PC species involved in CCTα regulation

• Pulse-chase analysis:

  • Short pulse labeling with deuterated or 13C-labeled precursors

  • Chase with unlabeled precursors to track the fate of newly synthesized PC species

  • Analyze labeled PC in different cellular compartments over time

• Functional consequences of specific PC species:

  • Correlate specific PC species with membrane properties using biophysical techniques

  • Examine effects of supplementation with defined PC species on cellular processes

Research using these approaches has begun to reveal that CEPT1 and CHPT1 produce PC with different fatty acid compositions, likely contributing to their distinct functions in cellular processes like lipid droplet formation and membrane dynamics .

What methods are recommended for studying CHPT1 in the context of the Kennedy pathway?

Studying CHPT1 within the Kennedy pathway requires integrated approaches that combine molecular, cellular, and biochemical techniques:

• Metabolic flux analysis:

  • Radiolabeled precursors (³H-choline, ³²P-phosphocholine) to track pathway flux

  • Stable isotope labeling to measure incorporation rates and intermediates

  • Time-course sampling to determine rate-limiting steps and regulatory points

• Enzyme activity assays:

  • In vitro assays using microsomal fractions to measure CHPT1 activity

  • Determination of enzyme kinetics (Km, Vmax) for different substrates

  • Comparative analysis between CHPT1 and CEPT1 activities under various conditions

• Genetic manipulation strategies:

  • CRISPR/Cas9 knockout models of individual Kennedy pathway enzymes

  • Combination knockouts to assess pathway interdependencies

  • Rescue experiments with wild-type or mutant constructs

• Organelle isolation and reconstitution:

  • Purification of Golgi membranes to study native CHPT1 in its physiological environment

  • Reconstitution of CHPT1 in liposomes to study activity independent of cellular context

  • Interorganelle contact site isolation to study phospholipid transfer mechanisms

• Integrated multi-omics approach:

  • Transcriptomics: Assess coordinated regulation of Kennedy pathway enzymes

  • Proteomics: Identify CHPT1 interaction partners and post-translational modifications

  • Lipidomics: Comprehensive analysis of phospholipid species and their dynamics

Research using these approaches has revealed that CHPT1 contributes approximately 50% of cellular PC synthesis, with the remaining PC being synthesized by CEPT1. Additionally, these studies have shown that CHPT1 selectively produces PC, while CEPT1 can produce both PC and PE (with PE synthesis being reduced by 80% in CEPT1-KO cells) .

What are the methodological approaches for investigating CHPT1's role in pathological conditions?

Investigating CHPT1's role in pathological conditions requires multidisciplinary approaches that connect molecular mechanisms to disease phenotypes:

• Clinical sample analysis:

  • Immunohistochemistry to assess CHPT1 expression in patient tissues

  • Gene expression analysis to identify alterations in CHPT1 and related pathway components

  • Correlative studies linking CHPT1 expression or variants with clinical outcomes

• Disease model systems:

  • CHPT1 knockout or knockdown in disease-relevant cell lines

  • Patient-derived cell models (primary cells or iPSCs) with CHPT1 manipulation

  • Animal models with tissue-specific CHPT1 deletion or overexpression

• Functional impact assessment:

  • Phospholipid profiling in disease states with altered CHPT1 function

  • Membrane integrity and fluidity measurements in CHPT1-deficient cells

  • Organelle stress responses (particularly ER and Golgi) in relation to CHPT1 dysregulation

• Therapeutic targeting approaches:

  • Small molecule inhibitor screening for CHPT1 modulation

  • Phospholipid supplementation strategies to bypass CHPT1 deficiencies

  • Gene therapy approaches for CHPT1-related disorders

• Cancer-specific methodologies:

  • Analysis of CHPT1 in relation to tumor progression and metastasis

  • Investigation of CHPT1's role in therapy resistance mechanisms

  • Studies of CHPT1 in cancer metabolic reprogramming

Research has begun to identify connections between CHPT1 and disease states, including a reported role in antiandrogen therapy resistance in prostate cancer through interaction with super enhancer activation and altered choline metabolism . These findings highlight the importance of CHPT1 as a potential therapeutic target in cancer and other phospholipid metabolism-related disorders.

What are the optimal storage and handling conditions for CHPT1 antibodies?

Proper storage and handling of CHPT1 antibodies are critical for maintaining their performance and prolonging their usable lifespan:

• Storage temperature:

  • Store at -20°C for long-term stability

  • Avoid repeated freeze-thaw cycles that can degrade antibody activity

  • For antibodies with glycerol, aliquoting is unnecessary for -20°C storage

• Buffer composition considerations:

  • Most CHPT1 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • This formulation provides stability during freeze-thaw and prevents microbial contamination

  • Note that some formulations may contain 0.1% BSA as a stabilizer

• Aliquoting recommendations:

  • For antibodies without glycerol, prepare small single-use aliquots

  • Use sterile techniques when handling to prevent contamination

  • Record date of first thaw and track antibody usage

• Short-term handling:

  • When working with the antibody, keep on ice or at 4°C

  • Return to -20°C promptly after use

  • Avoid extended periods at room temperature

• Shelf-life considerations:

  • Most CHPT1 antibodies remain stable for one year after shipment when properly stored

  • Monitor for signs of degradation such as precipitation or loss of activity

  • Consider validation tests if using antibodies near their expiration date

Following these storage and handling guidelines will help ensure consistent results and maximum antibody performance across experiments, reducing variability in experimental outcomes.

How can researchers troubleshoot non-specific binding or weak signals when using CHPT1 antibodies?

Troubleshooting non-specific binding or weak signals with CHPT1 antibodies requires systematic optimization of experimental conditions:

• For non-specific binding issues:

  • Blocking optimization: Test different blocking agents (5% BSA, 5% milk, commercial blockers) as the standard 3% milk may be insufficient for some samples

  • Antibody dilution: Increase dilution factor incrementally (e.g., from 1:500 to 1:1000 or 1:2000)

  • Wash stringency: Increase TBST concentration (0.1% to 0.3% Tween-20) or add salt (up to 500mM NaCl) to reduce non-specific interactions

  • Cross-adsorption: Consider pre-adsorbing antibody with related proteins or tissue lysates from knockout models

• For weak signal issues:

  • Protein loading: Increase sample concentration (up to 50μg per lane)

  • Antibody concentration: Decrease dilution factor (e.g., from 1:2000 to 1:1000)

  • Incubation conditions: Extend primary antibody incubation to overnight at 4°C

  • Detection system: Use more sensitive ECL substrates or switch to fluorescent detection

  • Signal enhancement: Consider using signal amplification systems (e.g., biotin-streptavidin)

• For both issues:

  • Sample preparation: Optimize lysis buffers and include phosphatase/protease inhibitors

  • Fresh antibody: Ensure antibody has not degraded through improper storage

  • Different antibody lots: Test multiple lots or sources of CHPT1 antibodies

  • Epitope accessibility: Try different antigen retrieval methods for fixed samples

• Validation approaches:

  • Use CHPT1 knockout or knockdown samples as negative controls

  • Include positive control samples with confirmed CHPT1 expression (e.g., DU145 cells)

  • Try antibodies targeting different epitopes of CHPT1

These methodical troubleshooting approaches can significantly improve CHPT1 detection specificity and sensitivity across various experimental applications.

What are the latest methodological advances in studying CHPT1 interactions with other proteins or cellular structures?

Recent methodological advances have expanded our ability to study CHPT1's protein interactions and structural associations:

• Proximity-based interactome mapping:

  • BioID or TurboID approaches using CHPT1 fusion proteins to identify proximal interactors

  • APEX2-based proximity labeling to capture transient interactions in native cellular compartments

  • Split-BioID systems to identify context-specific interactors in different cellular states

• Advanced microscopy techniques:

  • Super-resolution microscopy (STORM, PALM, STED) to visualize CHPT1 localization at nanoscale resolution

  • Correlative light and electron microscopy (CLEM) to connect CHPT1 localization with ultrastructural features

  • Live-cell imaging using split-fluorescent protein complementation to monitor dynamic interactions

• Membrane contact site analysis:

  • CHPT1 has been implicated in specialized membrane domains alongside PI synthase

  • Synthetic biology approaches using engineered membrane tethers to study functional consequences

  • In vitro reconstitution of membrane contact sites with purified components

• Structural biology approaches:

  • Cryo-electron microscopy to determine CHPT1 structure in membrane environments

  • Cross-linking mass spectrometry (XL-MS) to map interaction interfaces

  • Hydrogen-deuterium exchange mass spectrometry to identify dynamic regions involved in protein-protein interactions

• Functional protein arrays:

  • Protein microarrays to screen for novel CHPT1 interactors

  • Lipid-protein overlay assays to identify lipid-dependent interactions

  • Cell-free expression systems to study CHPT1 interactions without cellular complexity

These emerging methodologies have begun to reveal CHPT1's associations with components of specialized membrane domains, including focal adhesion kinase interacting protein of 200 kDa, UNC-51-like kinase, and Rab10, suggesting roles in autophagosome initiation and ER tubule dynamics beyond its canonical function in PC synthesis .

How can researchers integrate lipidomics approaches with CHPT1 functional studies?

Integrating lipidomics with CHPT1 functional studies provides powerful insights into phospholipid metabolism and cellular functions:

• Targeted lipidomics strategies:

  • Stable isotope labeling with choline precursors to track newly synthesized PC

  • Multiple reaction monitoring (MRM) mass spectrometry to quantify specific PC species

  • Ion mobility separation to distinguish isobaric lipid species with different structures

• Spatial lipidomics approaches:

  • Subcellular fractionation combined with lipidomics to analyze compartment-specific PC profiles

  • MALDI imaging mass spectrometry to visualize lipid distribution in tissues with CHPT1 manipulation

  • Clickable lipid analogs to track trafficking of CHPT1-derived phospholipids

• Temporal lipidomics analysis:

  • Time-course experiments after CHPT1 induction or inhibition

  • Pulse-chase studies with labeled precursors to determine turnover rates

  • Acute vs. chronic CHPT1 perturbation to distinguish immediate vs. adaptive changes

• Multi-omics integration approaches:

  • Correlate lipidomics data with transcriptomics and proteomics in CHPT1-manipulated systems

  • Network analysis to identify regulatory relationships between CHPT1 and lipid homeostasis

  • Machine learning algorithms to predict functional consequences of lipid profile changes

• Biophysical characterization:

  • Membrane fluidity measurements to assess functional impact of altered PC composition

  • Lipid domain analysis using fluorescent probes in CHPT1-deficient cells

  • Artificial membrane systems with defined lipid compositions to test biophysical hypotheses

This integrated approach has revealed that CHPT1 and CEPT1 produce PC with different fatty acid compositions, likely contributing to their distinct cellular functions. Studies have shown that CHPT1 accounts for approximately 50% of cellular PC synthesis, with characteristic lipid species profiles that differ from CEPT1-derived phospholipids .